Combination of Lenalidomide and Ofatumumab in Patients With Previously Treated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (CLL/SLL).
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 18 Apr 2017
At a glance
- Drugs Lenalidomide (Primary) ; Ofatumumab (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- 12 Apr 2017 Planned primary completion date changed from 1 Nov 2017 to 1 Jan 2019.
- 08 Apr 2016 Planned primary completion date changed from 1 Nov 2016 to 1 Nov 2017 as reported by ClinicalTrials.gov.
- 05 Jan 2016 Results published in the Clinical cancer research: an official journal of the American Association for Cancer Research